Moving vaccines through Indonesia's distributors and pharmacies: who chooses the outlet, and where the cold chain gets tested
Summary
- Indonesia has two vaccine supply chains: the public programme, supplied by a state-owned producer, where DTP3 coverage reached 82% in 2025 from 78% in 2024, and the self-paid market, an oligopoly of multinationals, where private distributors work. 1 2
- In the self-paid market the doctor is the channel: parents follow the paediatrician, who also steers patients to cheaper pharmacies. 3 4
- Distributors carry the cost: stock risk when buying outright, labour-heavy delivery and manufacturer targets set without seeing the work. 5 6 7
- The distribution standard issued in 2025 names vaccines and cold chain products, covers online B2B platforms, and carries sanctions up to loss of the certificate. 8 9
- Geography is the stress test: about 17,500 islands and 27.8% of districts classed as remote, with uptake uneven across provinces. 10
- The programme keeps widening, with 14 antigens and hexavalent planned nationwide, which shifts what the private lane sells; the local producer says its Bandung site cannot expand. 11 12
Transcript
01Two supply chains that look alike
You run cold chain for a pharmaceutical distributor in Jakarta. What should an outsider understand first about vaccines in Indonesia?
That there are two vaccine businesses here and they only look alike from outside. One is the government programme, supplied by a state-owned producer. The other is the self-paid market, an oligopoly of multinationals, and that is where a private distributor like us lives. 1 The public side is huge. UNICEF's latest figures put DTP3 coverage at 82% in 2025, up from 78% in 2024, and more than 3.6 million children finished the full DTP3 and HepB3 course in 2025. 2 I cannot tell you our share of any of that, because the public side is not our lane. 1
What surprises newcomers is who chooses the outlet. In the self-paid market the front line is the private paediatrician, and most parents simply follow the recommendation. 3 The doctor also steers: some send families to a pharmacy, because the vaccine there is cheaper than the hospital price. 4 So before a truck moves, a conversation in a consulting room has already decided where the box goes. 3
Do the gaps in the public numbers matter to your business?
As a mood, yes, not as a number I can plan with. UNICEF counts an estimated 748,000 zero-dose children in 2024, falling to 657,000 in 2025, so the public system is improving but not finished. 2 A parent who reads about missed children in the news is more likely to ask the paediatrician about the full schedule, and the paediatrician is exactly who decides on our side. 3 I would not tell a newcomer that public gaps are a private opportunity. It depends on the family and on the price. 13
02From manufacturer to doctor
Walk me through the chain on the private side.
The manufacturer sells to licensed distributors like us, we hold the stock in cold storage and deliver to hospitals, clinics, doctors and pharmacies. Each outlet orders in small quantities and often, because a vaccine is expensive and does not wait on a shelf. The manufacturer sets sales targets and a ceiling price for us, and that is where the friction starts. 7
Distribution is labour-heavy work with low productivity: many small drops, many drivers, many cold boxes. That cost does not disappear, it ends up in the retail price the parent sees. 6 If someone tells you the vaccine is expensive because of the manufacturer alone, they have not stood on a loading dock at six in the morning. 6
Do you buy outright or on consignment, and who holds the risk?
It depends on the customer and the product, and I will not tell you any one contract. What I can say is the principle: a pharmacy that buys outright carries a real profit-and-loss risk if stock goes unsold, and a vaccine cannot be shelved for later like a vitamin. 5 Consignment moves that risk back toward the distributor or the manufacturer. So when a pharmacy asks for consignment, I know the stock is slow before they say it. 5
A pharmacy also has little incentive to push vaccines, because medicines generate far more of its sales than vaccines do. 14 A pharmacy manager once explained it to me this way: the vaccine takes the same fridge space and far more attention. I have not seen his books, but the logic is plain. 14
03What manufacturers see and do not see
How do manufacturers manage distributors like you?
With targets and ceiling prices, mostly from a distance. The complaint I hear from colleagues is that manufacturers trust distributors too much: they set the target but do not see how the job is actually done on the road. 7 I understand both sides. A head office cannot ride along on every delivery. 7
The direction of travel is tighter control. Manufacturers were expected to look harder at distributor coverage, efficiency and cold storage, and the audits I see now ask for records, not promises. 15 My advice to a manufacturer entering: audit your distributors' fridges before you set their targets, not after. 15
And when something goes wrong with a brand, who hears first?
Often us. Doctors are loyal to a brand and rarely switch, unless supply fails or a defect appears. 16 I have seen a distributor's word about a manufacturer's problem be enough for one doctor to change brand, and after that inertia kept him on the new one. 17 That is a responsibility I take seriously, so I only say it when I am sure. 17
04The 2025 distribution standard and the cold chain
What changed in the rulebook for people in your job?
BPOM issued its new Good Distribution Practice regulation, number 20 of 2025. The head of BPOM set it on 24 June 2025, it was promulgated on 3 July 2025, and it replaces regulation number 9 of 2019 and its 2020 amendment. 8 The press release names vaccines as biological products inside the scope, and it adds detailed rules for cold chain products. 8 It also reaches electronic system operators running online business-to-business distribution, so a platform that connects buyers and sellers is no longer outside the net. 8
Who has to comply, and what if they do not?
The standard applies to pharmaceutical wholesalers, their branches and pharmaceutical management facilities, and it carries special provisions for cold chain products. 9 On breaches, the regulation lists a written warning, a temporary suspension of activity and/or revocation of the CDOB certificate. 9 For a distributor the last one is the real threat, because without the certificate the warehouse is a very expensive room. I have only read the text, I have not been through an inspection under the new version. 9
In daily life the standard turns into habits: temperature records you can show, a driver who knows what to do if the van stops, a cold box that is the right one for the route. 15 Manufacturers asked for stronger control before the regulation, so for serious distributors it formalises what customers already expect. 15
05Islands, remote districts and the last mile
How does geography change the job?
It decides everything outside Java. Indonesia is about 285 million people across about 17,500 islands, and 27.8% of districts are classed as remote. 10 For a private distributor that means we reach the cities and the larger towns well, and the far districts are served mostly through the public system, not through us. 18 I will not pretend we cover the whole archipelago. 18
Does the public side reach them?
Unevenly. Programme quality varies sharply between well-resourced cities and poorer provinces, because districts fund and run immunisation locally and many allocate far less than the ministry suggests. 18 The HPV programme shows it: it is delivered through schools using the puskesmas, and uptake has been uneven across provinces. 10 One report on the programme puts first-dose coverage at 29% and the second dose at 7% a year into the rollout, without saying whether that is national. 10
06Doctors, pharmacies and who sells to whom
You said doctors decide. Why do they matter so much to the channel?
Because the parent does not shop for vaccines, the parent shops for a doctor. Private paediatricians earn from the vaccine, the consultation and the syringe, so they have a reason to stock and recommend, while a hospital-employed doctor is salaried and thinks differently. 19 The paediatric society's schedule matters too: its working group sets the recommended list and paediatricians follow it closely, and expensive vaccines are more likely to be listed as optional. 20
And the pharmacies, are they gaining?
They reach further than before: clinics and solo-practice doctors are now regular customers, and they sell cheaper than hospitals. 21 But a patient does not walk in alone. The doctor sends them. 21 That is why I treat a pharmacy as an extension of the doctor's recommendation, not as a competing consumer brand. 4
Who is the buyer you would target first?
07When the programme widens, and what worries me
What happens to the private lane when a vaccine enters the national programme?
It shrinks for that vaccine, and the private lane moves to the next one. A vaccine is judged on mortality, morbidity and cost-benefit, and budget is the binding constraint, so entry is slow and political. 22 The Ministry of Health's immunization director said the state already provides 14 antigens through routine immunization, with rotavirus, PCV and HPV among the more recent additions. 11 The same briefing planned hexavalent vaccine from the third quarter of 2025 in 3 provinces, with nationwide implementation to follow in 2026. 11
What would you tell a foreign vaccine maker or logistics firm entering?
Choose your distributor for its fridges, not its relationships, and audit them. 15 Write targets you can see being met, because manufacturers who set targets blind get surprised. 7 And spend time with the paediatricians' society before you spend money on trucks. 20
What worries you, and what would change your mind?
Local supply. Bio Farma has capacity of 3.1 billion doses a year and secured Rp 1.4 trillion in export contracts for vaccines starting in 2025, but its deputy president director says expansion is not feasible at the 130-year-old Bandung facility. 12 If export demand grows faster than a site that cannot expand, I worry about domestic supply. 12 I would change my mind if the producer shows a new site, because the whole chain is easier when supply does not fail. 16
The other worry is quieter. A cold chain that works every day is invisible, and a cold chain that fails is a headline, so budgets for fridges are the first thing cut when there is a squeeze. 6 The new standard helps, and the sanctions are there, but sanctions arrive after the failure. 9
Sources and basis
- 1The public immunisation programme is supplied by a state-owned producer, while the self-paid vaccine market is an oligopoly of multinational manufacturersKIRA field interviews · KIRA field interviews, Indonesia vaccine channel
- 2UNICEF Indonesia, citing the 2025 WHO/UNICEF immunization coverage estimates released 20 July 2026: DTP3 coverage was 78% in 2024 and 82% in 2025; the estimated number of zero-dose children (no vaccine doses) fell from 748,000 in 2024 to 657,000 in 2025; more than 3.6 million children received the full DTP3/HepB3 course in 2025; HPV coverage rose while several other vaccines stayed flat or declinedPublic source · UNICEF Indonesia press release, July 2026 · link
- 3Private paediatricians are the front line of self-paid vaccine sales, and most parents follow the doctor's recommendationKIRA field interviews · KIRA field interviews, Indonesia vaccine channel
- 4Some doctors send patients to pharmacies, which sell vaccines cheaper than the hospital priceKIRA field interviews · KIRA field interviews, Indonesia vaccine channel
- 5Pharmacies buying vaccines outright, rather than on consignment, carry a real profit-and-loss risk from unsold stockKIRA field interviews · KIRA field interviews, Indonesia vaccine channel
- 6Vaccine distribution is labour-heavy with low productivity, which raises costs that are passed on in retail pricesKIRA field interviews · KIRA field interviews, Indonesia vaccine channel
- 7Manufacturers set sales targets and ceiling prices for distributors but often do not see how distributors actually perform; distributors say manufacturers trust them too muchKIRA field interviews · KIRA field interviews, Indonesia vaccine channel
- 8BPOM press release of 8 Aug 2025: BPOM Regulation No. 20 of 2025 on Good Distribution Practice (CDOB) was set by the BPOM head on 24 June 2025 and promulgated on 3 July 2025; it replaces BPOM Regulation No. 9 of 2019 and its amendment, BPOM Regulation No. 6 of 2020; it covers distribution of human medicines including biological products such as vaccines, contains detailed rules for cold chain products (CCP), and extends to electronic system operators running online B2B distributionPublic source · BPOM press release, 8 Aug 2025 · link
- 9BPOM Regulation No. 20 of 2025 (CDOB), Article 2: the standard applies to pharmaceutical wholesalers (PBF), PBF branches and pharmaceutical management facilities, and includes special provisions for cold chain products (CCP); Article 6: sanctions for violations are a written warning, temporary suspension of activity and/or revocation of the CDOB certificatePublic source · BPOM Regulation No. 20 of 2025, text hosted on pasal.id, accessed Oct 2026 · link
- 10Think Global Health, 5 May 2026: Indonesia's roughly 285 million people are spread across about 17,500 islands and 27.8% of districts are classified as remote; HPV doses are delivered through a school-based programme that uses public health centres (puskesmas) in August and November; the article says that "a year later" (after an earlier expansion of the pilot; it does not say whether the figure is national) HPV coverage reached 29% for the first dose and 7% for the second; uptake is uneven across provinces; national coverage data after the launch had not yet been reportedPublic source · Think Global Health, 5 May 2026 · link
- 11ANTARA News, 11 Apr 2025, quoting the Ministry of Health's director of immunization: the state provides 14 antigens through routine immunization, with rotavirus, PCV and HPV as three additional antigens; hexavalent vaccine (pentavalent plus IPV) was to start in the third quarter of 2025 in 3 provinces (Yogyakarta, Bali and West Nusa Tenggara), with nationwide implementation to follow in 2026 (a plan as announced)Public source · ANTARA News, 11 Apr 2025 · link
- 12The Jakarta Post, 4 Nov 2024: Bio Farma secured Rp 1.4 trillion (US$88.9 million) in vaccine export contracts starting in 2025 for polio, diphtheria, tetanus and pertussis vaccines, covering half of its Rp 3 trillion annual target; production capacity of 3.1 billion doses a year, ranking among the world's 7 largest vaccine makers; plan to raise output fivefold over 10 years; expansion not feasible at its 130-year-old Bandung facility because of limited land and safety concerns about nearby residences, per its deputy president directorPublic source · The Jakarta Post, 4 Nov 2024 · link
- 13Self-paid demand is concentrated in upper-middle and high-income urban families, who increasingly ask for vaccines after reading parenting media and the internetKIRA field interviews · KIRA field interviews, Indonesia vaccine channel
- 14Medicines generate far more pharmacy sales than vaccines doKIRA field interviews · KIRA field interviews, Indonesia vaccine channel
- 15Manufacturers were expected to tighten control over distributor coverage, efficiency and cold storageKIRA field interviews · KIRA field interviews, Indonesia vaccine channel
- 16Doctors are loyal to a vaccine brand and rarely switch unless supply fails or a defect appears; inertia keeps them on the new brand afterwardsKIRA field interviews · KIRA field interviews, Indonesia vaccine channel
- 17A distributor's word about a manufacturer's problems was enough for one doctor to switch brandsKIRA field interviews · KIRA field interviews, Indonesia vaccine channel
- 18Programme quality varies sharply between well-resourced cities and poorer provinces, because decentralisation leaves districts to fund and run immunisation locally and many allocate far less than the ministry suggestsKIRA field interviews · KIRA field interviews, Indonesia health officials
- 19Private paediatricians earn from the vaccine, the consultation and the syringe, while hospital-employed doctors are salariedKIRA field interviews · KIRA field interviews, Indonesia vaccine channel
- 20The paediatric society's immunisation working group decides the recommended schedule and paediatricians follow it closely; expensive vaccines are more likely to be listed as optional than mandatoryKIRA field interviews · KIRA field interviews, Indonesia medical societies
- 21Pharmacies extend their reach to clinics and solo-practice doctors, and patients do not come to the pharmacy on their own: the doctor sends themKIRA field interviews · KIRA field interviews, Indonesia vaccine channel
- 22A vaccine joins the national programme on mortality, morbidity and cost-benefit, and budget is the binding constraintKIRA field interviews · KIRA field interviews, Indonesia health officials